Michael D. Green

发表

High-affinity anti-oestrogen binding site distinct from the oestrogen receptor

L. Murphy, R. Sutherland, Z. Krozowski, 1980, Nature.

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

H. Hurwitz, D. Rischin, M. Rosenthal, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.

N. Petrelli, D. Stablein, R. Mayer, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin.

A H Kaye, R L Nation, S. Stylli, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle.

I. Taylor, R. Sutherland, M. Green, 1983, European journal of cancer & clinical oncology.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

M. Piccart, J. Baselga, P. Gascón, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

C. Begley, J. Rasko, C. Begley, 1996, The Lancet.

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.

N. Colombo, H. Hochster, F. Muggia, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens.

R. Sutherland, M. Green, R. Reddel, 1983, European journal of cancer & clinical oncology.

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.

C. Begley, J. Zalcberg, I. Davis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.

A. Burgess, A. Boyd, J. Cebon, 1989, Annals of internal medicine.

EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY

M. Green, W. Sheridan, D. Metcalf, 1988, The Lancet.

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

V. Ferrans, A. Zeleniuch‐Jacquotte, H. Hochster, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.

L. To, M. Green, R. Abraham, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

New anthracycline antitumor antibiotics.

M. Green, F. Muggia, Michael D. Green, 1991, Critical reviews in oncology/hematology.

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.

J. Rasko, C. Begley, J. Zalcberg, 1997, Blood.

Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.

M. Green, M D Green, P M Alderton, 1992, Cancer research.